Cover Image

Association between Plasma PCSK9 levels and Presence of Coronary Artery Calcium

Saved in:

Bibliographic Details
Main Authors:	Tahir Mahmood (Author), Jessica Minnier (Author), Joshua Miles (Author), Bruce Warden (Author), Sergio Fazio (Author), Michael D. Shapiro (Author)
Format:	Book
Published:	Elsevier, 2020-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol
by: Bruce A. Warden, et al.
Published: (2020)

Unusual Responses to PCSK9 Inhibitors in a Real-world Clinical Cohort
by: Bruce A. Warden, et al.
Published: (2020)

PCSK9 - new perspectives for lipid-lowering pharmacotherapy in patients with coronary artery disease
by: Natalia Pauli, et al.
Published: (2020)

Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
by: Maya Safarova, et al.
Published: (2024)

PCSK9 INHIBITORS IN PERIPHERAL ARTERY DISEASE: REVIEW OF EFFICACY, SAFETY, AND OUTCOMES
by: Moiud Mohyeldin
Published: (2024)

A Comprehensive Review of PCSK9 Inhibitors
by: Caroline Coppinger BS, et al.
Published: (2022)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
by: Martin Jozef Péč, et al.
Published: (2023)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
by: Kosmas CE, et al.
Published: (2020)

Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
by: K. O. Shnaider, et al.
Published: (2023)

Effect of Triglyceride-Glucose Indices and Circulating PCSK9-Associated Cardiovascular Risk in STEMI Patients with Primary Percutaneous Coronary Artery Disease: A Prospective Cohort Study
by: Zhao X, et al.
Published: (2023)

The Role of PCSK9 Inhibitors in the Improvement of Outcomes in Patients after Acute Coronary Syndrome: Results of ODYSSEY OUTCOMES Trial
by: Yu. A. Karpov
Published: (2019)

Sex difference in circulating PCSK9 and its clinical implications
by: Fang Jia, et al.
Published: (2022)

The wind of change - PCSK9 inhibitors in hypolipidemic treatment. The Polish perspective
by: Natalia Ilnicka, et al.
Published: (2023)

Inclisiran-Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
by: Łukasz Wołowiec, et al.
Published: (2023)

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
by: Saeideh Sobati, et al.
Published: (2020)

PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
by: article Editorial
Published: (2023)

Assessment of the 9p21.3 locus in severity of coronary artery disease in the presence and absence of type 2 diabetes
by: Rivera Natalia V, et al.
Published: (2013)

Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk
by: Alessia Silla, et al.
Published: (2023)

Coronary artery calcium score: Gated or non-gated?
by: İbrahim Altun
Published: (2021)

Correlations Between Coronary Artery Disease, Coronary Artery Calcium Score, and Lipoprotein(a) Level in Korea
by: Kim J, et al.
Published: (2022)

COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH PCSK9 INHIBITORS VS. STATIN INTOLERANCE
by: Mohsin Haseeb, et al.
Published: (2023)

PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke
by: Lin Zhou, et al.
Published: (2024)

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
by: A. V. Blokhina, et al.
Published: (2022)

An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
by: Hye Duck Choi, et al.
Published: (2023)

PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
by: A. A. Nekipelova, et al.
Published: (2023)

Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors
by: Paul C Langley, Dr
Published: (2017)

The therapeutic effect of PCSK9 inhibitors on dyslipidemia: one-year follow up
by: Maryam Moshkani Farahani, et al.
Published: (2024)

Relation of neutrophil/lymphocyte ratio with the presence and severity of coronary artery ectasia
by: S. Selim Ayhan, et al.
Published: (2013)

Association of neutrophil to lymphocyte ratio with presence of isolated coronary artery ectasia
by: Turgay Isik, et al.
Published: (2013)

Coronary Artery Calcium (CAC) Scoring and Treatment Decision Making
by: Richard M Fleming, et al.
Published: (2019)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
by: Vittoria Cammisotto, et al.
Published: (2022)

The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process - is there a link?
by: Malwina Grobelna, et al.
Published: (2019)

Plasma Concentrations of Adiponectin in Patients with Coronary Artery Disease and Coronary Slow Flow
by: Muhammad Diah, et al.
Published: (2019)

Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study
by: Hailing Liu
Published: (2024)

Genetic variations in HMGCR and PCSK9 and kidney function: a Mendelian randomization study
by: Sehoon Park, et al.
Published: (2023)

PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation
by: Elena Dozio, et al.
Published: (2020)

Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?
by: Rosaria Vincenza Giglio BD, PhD, et al.
Published: (2023)

Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis
by: Yousuf Zafar, et al.
Published: (2020)

Peculiarities of platelet hemostasis changes in patients with arterial hypertension and coronary artery disease, depending on the presence of microalbuminuria
by: Anna I. Pastushyna
Published: (2016)